Indiqube Spaces Ltd
INDIQUBEIndiqube Spaces Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding.
The price is in a downtrend (34 weeks in). Underneath, the last four quarters read improving. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Indiqube Spaces Ltd trades at ₹174, in a downtrend and 34 weeks into that stage. That is −3.4% against its own 200-day average. It sits at 39% of a 52-week range of ₹134 to ₹238. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 2 straight weeks.
Today the stock is in a downtrend — week 34 of stage 4, confirmed. At ₹174 it trades −3.4% versus its 200-day average and sits at 39% of its 52-week range (₹134–₹238).
Against the market, two honest reads. Cumulative: over the last 1.0 years the stock moved −20% while the NIFTY 500 moved +4% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 2 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
P/E does not price Indiqube Spaces Ltd — earnings are negative, so there is no multiple to rank against its own history. The revenue and margin lines below are where a turn, when it comes, would show first. On sales the market values Indiqube Spaces Ltd at 2.5× its FY26 revenue of ₹1,451 Cr.
With earnings negative, P/E does not price — there is no multiple to rank against its own history. The revenue and margin lines below are where the turn, when it comes, will show first.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Indiqube Spaces Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 4 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +37.0% | +35.8% | +37.6% | — |
| Share price | −20.2% | — | — | — |
4-Factor Sector Score
49.3/100 — rank 33 of 36 in Miscellaneous · 46% evidence confidence · provisional, ranked below fully-evidenced peers
Indiqube Spaces Ltd scores 49.3 out of 100 against the 36 companies it is compared with in Miscellaneous, ranking 33. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 20.9 + 9.6 + 10 + 8.8 = 49.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Indiqube Spaces Ltd reported ₹401 Cr of revenue in the Mar 26 quarter, +35.0% year on year. That is the 4th straight quarter of year-on-year growth. Over 6 years it has compounded at 35.0% a year. The last full year, FY26, came in at ₹1,451 Cr. The last four reported quarters add to ₹1,450 Cr.
FY26 revenue came in at ₹1,451 Cr (+37.0% on the year), capping 6 years at 35.0% compound. The latest quarter (Mar 26) printed ₹401 Cr, +35.0% year on year — the 4th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +36.8% growth against the decade's 35.0% — the current year is running faster than its own long-run rate.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Indiqube Spaces Ltd's operating margin is 62.0% in the Mar 26 quarter, +5.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 7 fiscal years the operating margin has ranged 10.0% to 61.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 62.0%, +5.0 pp against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 10.0%–61.0%, and FY26's 61.0% is the top of that band — a record year.
Why the margin moved: operating margin went +4.5 pp year on year while gross margin went −0.8 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Indiqube Spaces Ltd posted a net loss of ₹23.0 Cr in the Mar 26 quarter. The full FY26 year was a loss of ₹106 Cr. That loss is 5.7% of the quarter's revenue. The same quarter a year earlier lost ₹31.0 Cr. 8 of the last 8 reported quarters were loss-making.
Mar 26 profit was ₹−23.0 Cr, null year on year. On the full year, FY26 printed ₹−106 Cr (null).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Indiqube Spaces Ltd's cash-flow history is too thin to judge how much reported profit converts into cash. In FY26 that was ₹920 Cr of operating cash against ₹−106 Cr of profit. After ₹1,885 Cr of capital spending, ₹−965 Cr was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.
FY26: operating cash of ₹920 Cr against reported profit of ₹−106 Cr, leaving free cash of ₹−965 Cr after ₹1,885 Cr of capital spending.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Router verdict: the bigger cash user is investment — capital spending ran 2.8× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Indiqube Spaces Ltd's cash conversion cycle runs −273 days in FY26, down from 26 days in FY21. Capital spending ran ₹4,263 Cr over the last 3 years. At FY26 sales of ₹1,451 Cr each day of that cycle holds about ₹4.0 Cr, so roughly ₹−1,085 Cr sits inside the business at any moment.
FY26: debtors at 28 days, inventory at 3 days — roughly 0.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −273 days, tighter than FY21's 26.
The full loop: cash goes out to suppliers and production on day 0; stock waits 3 days to sell; customers pay about 28 days after that; and suppliers themselves are paid at 304 days — netting out to the −273-day cycle.
In money terms: at FY26 sales of ₹1,451 Cr, each day of the cycle holds about ₹4.0 Cr — so the −273-day loop keeps roughly ₹−1,085 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹4,263 Cr over the last 3 fiscal years against ₹1,524 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹96.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Indiqube Spaces Ltd earns a ROCE of 6% in FY26. That is up from a trough of −7% in FY22. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is −7.3% net margin on 0.22× asset turns.
FY26 ROCE is 6%, recovered from a FY22 trough of −7% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): −7.3% net margin × 0.22× asset turns × 12.64× balance-sheet leverage ≈ −20.3% on equity. Margin does its share; leverage is a meaningful part of the equation.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 6.0% on reported income across 8 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Indiqube Spaces Ltd carries ₹5,207 Cr of borrowings against ₹515 Cr of equity in FY26, a debt-to-equity of 10.11. Operating profit covers the interest bill 2×. Over 5 years borrowings went from ₹154 Cr to ₹5,207 Cr. Capital spending ran ₹4,263 Cr across the last 3 of those years.
FY26: borrowings of ₹5,207 Cr against equity of ₹515 Cr — a debt-to-equity of 10.11. Operating profit covers the interest bill 2×. Over 5 years borrowings went from ₹154 Cr to ₹5,207 Cr while capital spending ran ₹4,263 Cr in just the last 3 — part of the build-out is riding on borrowed money.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 6.0% on reported income across 8 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Indiqube Spaces Ltd moved a full percentage point over the last two years — the register is quiet. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — .
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Indiqube Spaces Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1IIRM Holdings India Ltd526530 | 66.2/100Favorable setup71% evidence | LEADER | 17.7/35 Revenue 14.9% · PAT 12.7% · OPM change 8.4 pp 83% evidence | 19.1/25 ROCE 20.4% · OPM 24.8% 76% evidence | 9.7/20 P/E 40.4× · PEG — 15% evidence | 19.7/20 RS sector 49.6% · RS bench 53.5% · 1Y 67.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 19.1 + 9.7 + 19.7 = 66.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Sagility LtdSAGILITY | 66.1/100Favorable setup87% evidence | TURNING | 24.4/35 Revenue 29.4% · PAT 49.3% · OPM change 0 pp 100% evidence | 15.5/25 ROCE 13.4% · OPM 22% 100% evidence | 14.2/20 P/E 19.8× · PEG 1.05 65% evidence | 12.0/20 RS sector 7.2% · RS bench -5% · 1Y -1.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 24.4 + 15.5 + 14.2 + 12 = 66.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Gulshan Polyols LtdGULPOLY | 65.2/100Favorable setup75% evidence | TURNING | 24.8/35 Revenue 35.2% · PAT 87% · OPM change 4.3 pp 59% evidence | 12.3/25 ROCE 6.3% · OPM 8% 95% evidence | 10.5/20 P/E 28.9× · PEG — 50% evidence | 17.6/20 RS sector 16.1% · RS bench 19.4% · 1Y 16.1%10 of 12 weeks ahead 100% evidence |
| Exact sum: 24.8 + 12.3 + 10.5 + 17.6 = 65.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Exhicon Events Media Solutions Ltd543895 | 64.4/100Thin evidence · provisional60% evidence | ASLEEP | 19.3/35 Revenue 100% · PAT 100% · OPM change 0 pp 48% evidence | 20.1/25 ROCE 29.5% · OPM 28% 76% evidence | 13.6/20 P/E 19.2× · PEG — 50% evidence | 11.4/20 RS sector 2.2% · RS bench -1.2% · 1Y -7.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 19.3 + 20.1 + 13.6 + 11.4 = 64.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5GMR Airports LtdGMRAIRPORT | 59.8/100Mixed-positive evidence71% evidence | BREAKING OUT | 22.8/35 Revenue 42.2% · PAT 100% · OPM change 2 pp 65% evidence | 14.2/25 ROCE 11.6% · OPM 37% 100% evidence | 8.6/20 P/E 534× · PEG — 15% evidence | 14.2/20 RS sector 3.3% · RS bench 6.5% · 1Y 17.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 22.8 + 14.2 + 8.6 + 14.2 = 59.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Aeroflex Enterprises LtdAEROENTER | 59.3/100Mixed-positive evidence83% evidence | LEADER | 16.8/35 Revenue 20.4% · PAT 4.9% · OPM change 1 pp 83% evidence | 16.0/25 ROCE 12.6% · OPM 18% 95% evidence | 8.1/20 P/E 20.9× · PEG — 50% evidence | 18.4/20 RS sector 24.8% · RS bench 28.1% · 1Y 16%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.8 + 16 + 8.1 + 18.4 = 59.3 · Decision use: Price leads the evidence: RS versus the benchmark is 28.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 7Global Education LtdGLOBAL | 59.3/100Mixed-positive evidence76% evidence | ASLEEP | 16.6/35 Revenue 29.9% · PAT -5.5% · OPM change 7.5 pp 83% evidence | 19.4/25 ROCE 29.2% · OPM 47% 95% evidence | 10.8/20 P/E 20× · PEG — 15% evidence | 12.5/20 RS sector 12.5% · RS bench 15.9% · 1Y 56.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 19.4 + 10.8 + 12.5 = 59.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Take Solutions LtdTAKE | 58.9/100Mixed-positive evidence63% evidence | 25.1/35 Revenue — · PAT 100% · OPM change 2932.2 pp 57% evidence | 8.3/25 ROCE 11.2% · OPM — 80% evidence | 8.5/20 P/E 3222× · PEG — 15% evidence | 17.0/20 RS sector 68% · RS bench 71.4% · 1Y 305.2%11 of 12 weeks ahead to 2026-05-03 100% evidence | |
| Exact sum: 25.1 + 8.3 + 8.5 + 17 = 58.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9R K Swamy LtdRKSWAMY | 58.5/100Mixed-positive evidence61% evidence | TURNING | 22.5/35 Revenue 15.9% · PAT 21.1% · OPM change 3 pp 83% evidence | 16.9/25 ROCE 12.3% · OPM 22% 95% evidence | 10.4/20 P/E 21.2× · PEG — 15% evidence | 8.7/20 RS sector — · RS bench -11.2% · 1Y —3 of 3 weeks ahead 25% evidence |
| Exact sum: 22.5 + 16.9 + 10.4 + 8.7 = 58.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Jai Corp LtdJAICORPLTD | 57.6/100Mixed-positive evidence70% evidence | ASLEEP | 24.1/35 Revenue -0.6% · PAT 100% · OPM change 5 pp 83% evidence | 15.3/25 ROCE 13.3% · OPM 13% 95% evidence | 11.5/20 P/E 10.4× · PEG — 15% evidence | 6.7/20 RS sector -8.2% · RS bench -18.9% · 1Y -1.9%4 of 10 weeks ahead 70% evidence |
| Exact sum: 24.1 + 15.3 + 11.5 + 6.7 = 57.6 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -8.2% and the one-year return is -1.9%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 11Aegis Vopak Terminals LtdAEGISVOPAK | 56.0/100Thin evidence · provisional56% evidence | TURNING | 21.4/35 Revenue 25.6% · PAT 76.7% · OPM change 2 pp 83% evidence | 13.4/25 ROCE 7.6% · OPM 74% 76% evidence | 9.1/20 P/E 104× · PEG — 15% evidence | 12.1/20 RS sector — · RS bench 22% · 1Y 13%5 of 10 weeks ahead 25% evidence |
| Exact sum: 21.4 + 13.4 + 9.1 + 12.1 = 56 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Parin Enterprises LtdPARIN | 54.3/100Mixed-positive evidence63% evidence | BREAKING OUT | 19.7/35 Revenue 100% · PAT 100% · OPM change -3 pp 48% evidence | 11.7/25 ROCE 10.8% · OPM 9% 95% evidence | 9.0/20 P/E 123× · PEG — 15% evidence | 13.9/20 RS sector 13.1% · RS bench 16.5% · 1Y 94.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 11.7 + 9 + 13.9 = 54.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Inox Green Energy Services LtdINOXGREEN | 50.7/100Mixed-positive evidence65% evidence | ASLEEP | 24.7/35 Revenue 24.6% · PAT 100% · OPM change 0.5 pp 83% evidence | 9.5/25 ROCE 8.4% · OPM -4.1% 76% evidence | 9.3/20 P/E 66× · PEG — 15% evidence | 7.2/20 RS sector -8.6% · RS bench -8.4% · 1Y -1.1%6 of 10 weeks ahead 70% evidence |
| Exact sum: 24.7 + 9.5 + 9.3 + 7.2 = 50.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Eveready Industries India LtdEVEREADY | 48.3/100Mixed-negative evidence90% evidence | TURNING | 17.6/35 Revenue 8.2% · PAT 100% · OPM change 0 pp 88% evidence | 14.9/25 ROCE 17.2% · OPM 9% 100% evidence | 8.1/20 P/E 24.9× · PEG 2.1 100% evidence | 7.7/20 RS sector -9.5% · RS bench -3% · 1Y -19.9%4 of 10 weeks ahead 70% evidence |
| Exact sum: 17.6 + 14.9 + 8.1 + 7.7 = 48.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15TCC Concept LtdTCC | 47.3/100Mixed-negative evidence81% evidence | ASLEEP | 17.3/35 Revenue 100% · PAT 51.1% · OPM change -45 pp 95% evidence | 11.4/25 ROCE 5.7% · OPM 36% 95% evidence | 14.1/20 P/E 20.9× · PEG — 50% evidence | 4.5/20 RS sector -17.6% · RS bench -35% · 1Y -44.2%0 of 11 weeks ahead 70% evidence |
| Exact sum: 17.3 + 11.4 + 14.1 + 4.5 = 47.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16GKW LtdGKWLIMITED | 46.7/100Mixed-negative evidence63% evidence | ASLEEP | 20.7/35 Revenue -2.1% · PAT 87.5% · OPM change 2160.4 pp 83% evidence | 6.7/25 ROCE 0.5% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.3/20 RS sector -0.9% · RS bench -5% · 1Y -8.8%4 of 10 weeks ahead 70% evidence |
| Exact sum: 20.7 + 6.7 + 10 + 9.3 = 46.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Prozone Realty LtdPROZONER | 43.4/100Mixed-negative evidence68% evidence | ASLEEP | 21.2/35 Revenue 9.2% · PAT 100% · OPM change 23 pp 62% evidence | 11.2/25 ROCE 6.1% · OPM 34.5% 95% evidence | 9.6/20 P/E 59.4× · PEG — 15% evidence | 1.4/20 RS sector -23% · RS bench -20.5% · 1Y -0.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 11.2 + 9.6 + 1.4 = 43.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Jindal Photo LtdJINDALPHOT | 41.5/100Mixed-negative evidence67% evidence | ASLEEP | 14.6/35 Revenue 100% · PAT -80% · OPM change -1015.9 pp 83% evidence | 5.9/25 ROCE -1.4% · OPM -932.6% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 11.0/20 RS sector 6.3% · RS bench -13.8% · 1Y 23.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 14.6 + 5.9 + 10 + 11 = 41.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Aqylon Nexus LtdAQYLON | 41.4/100Thin evidence · provisional54% evidence | ASLEEP | 12.7/35 Revenue 30.8% · PAT -52.5% · OPM change -2377.7 pp 48% evidence | 16.8/25 ROCE 39.2% · OPM — 80% evidence | 8.7/20 P/E 168.9× · PEG — 15% evidence | 3.2/20 RS sector -41.3% · RS bench -74.1% · 1Y -68.5%0 of 10 weeks ahead 70% evidence |
| Exact sum: 12.7 + 16.8 + 8.7 + 3.2 = 41.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Kaveri Seed Company LtdKSCL | 41.2/100Mixed-negative evidence82% evidence | ASLEEP | 18.1/35 Revenue 15.9% · PAT 5% · OPM change 3 pp 65% evidence | 12.6/25 ROCE 18.8% · OPM -15% 100% evidence | 5.1/20 P/E 13.6× · PEG 2.98 100% evidence | 5.4/20 RS sector -17.2% · RS bench -18.7% · 1Y -30.4%5 of 11 weeks ahead 70% evidence |
| Exact sum: 18.1 + 12.6 + 5.1 + 5.4 = 41.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21TruAlt Bioenergy LtdTRUALT | 40.8/100Mixed-negative evidence63% evidence | ASLEEP | 11.1/35 Revenue 1.8% · PAT -8.1% · OPM change 7 pp 100% evidence | 9.4/25 ROCE 10.8% · OPM 21% 100% evidence | 10.3/20 P/E 23.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —8 of 12 weeks ahead 0% evidence |
| Exact sum: 11.1 + 9.4 + 10.3 + 10 = 40.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Delta Corp LtdDELTACORP | 38.6/100Mixed-negative evidence77% evidence | ASLEEP | 11.2/35 Revenue -6.5% · PAT -66.4% · OPM change -5 pp 83% evidence | 9.6/25 ROCE 5% · OPM 17% 95% evidence | 12.5/20 P/E 18.9× · PEG — 50% evidence | 5.3/20 RS sector -18.1% · RS bench -11.6% · 1Y -28.9%6 of 10 weeks ahead 70% evidence |
| Exact sum: 11.2 + 9.6 + 12.5 + 5.3 = 38.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Shipping Corporation of India Land & Assets LtdSCILAL | 33.7/100Adverse evidence68% evidence | ASLEEP | 15.6/35 Revenue 27.3% · PAT 100% · OPM change -284.4 pp 62% evidence | 4.7/25 ROCE 1.3% · OPM -349.6% 95% evidence | 9.2/20 P/E 66.6× · PEG — 15% evidence | 4.2/20 RS sector -15.5% · RS bench -12.7% · 1Y -19.8%3 of 12 weeks ahead 100% evidence |
| Exact sum: 15.6 + 4.7 + 9.2 + 4.2 = 33.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Unitech LtdUNITECH | 32.0/100Adverse evidence65% evidence | ASLEEP | 12.8/35 Revenue 59% · PAT 5% · OPM change -584 pp 62% evidence | 6.1/25 ROCE 0.1% · OPM 184% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.1/20 RS sector -27.3% · RS bench -24.8% · 1Y -42.1%3 of 12 weeks ahead 100% evidence |
| Exact sum: 12.8 + 6.1 + 10 + 3.1 = 32 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Stanley Lifestyles LtdSTANLEY | 31.5/100Adverse evidence70% evidence | TURNING | 8.4/35 Revenue -1.6% · PAT -55.5% · OPM change -5.2 pp 83% evidence | 10.3/25 ROCE 6.4% · OPM 14.9% 95% evidence | 9.5/20 P/E 62.7× · PEG — 15% evidence | 3.3/20 RS sector -43.7% · RS bench -23.7% · 1Y -53.6%3 of 10 weeks ahead 70% evidence |
| Exact sum: 8.4 + 10.3 + 9.5 + 3.3 = 31.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26RattanIndia Enterprises LtdRTNINDIA | 29.3/100Adverse evidence62% evidence | ASLEEP | 13.8/35 Revenue 5.4% · PAT -80% · OPM change 19 pp 65% evidence | 1.6/25 ROCE -4.8% · OPM -6% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.9/20 RS sector -32.1% · RS bench -23% · 1Y -45%6 of 10 weeks ahead 70% evidence |
| Exact sum: 13.8 + 1.6 + 10 + 3.9 = 29.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Embassy Developments LtdEMBDL | 26.2/100Adverse evidence68% evidence | BREAKING OUT | 4.3/35 Revenue -20.6% · PAT -80% · OPM change -76.9 pp 83% evidence | 3.6/25 ROCE -2.4% · OPM -76% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.3/20 RS sector -17.2% · RS bench -14.6% · 1Y -45.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 4.3 + 3.6 + 10 + 8.3 = 26.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Central Mine Planning & Design Institute LtdCMPDI | 62.2/100Thin evidence · provisional38% evidence | TURNING | 22.3/35 Revenue — · PAT — · OPM change 8 pp 32% evidence | 19.8/25 ROCE 38.1% · OPM 30% 95% evidence | 10.1/20 P/E 26.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —3 of 3 weeks ahead 0% evidence |
| Exact sum: 22.3 + 19.8 + 10.1 + 10 = 62.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29FlySBS Aviation LtdFLYSBS | 54.7/100Thin evidence · provisional41% evidence | TURNING | 15.4/35 Revenue — · PAT — · OPM change -8 pp 26% evidence | 18.9/25 ROCE 32.5% · OPM 21% 95% evidence | 11.4/20 P/E 13.3× · PEG — 15% evidence | 9.0/20 RS sector — · RS bench -6.8% · 1Y 4.4%3 of 10 weeks ahead 25% evidence |
| Exact sum: 15.4 + 18.9 + 11.4 + 9 = 54.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30Qualitek Labs Ltd544091 | 53.7/100Thin evidence · provisional29% evidence | 17.3/35 Revenue — · PAT — · OPM change -3 pp 7% evidence | 15.0/25 ROCE 11.9% · OPM 26% 76% evidence | 9.8/20 P/E 33.6× · PEG — 15% evidence | 11.6/20 RS sector — · RS bench 9.1% · 1Y — 25% evidence | |
| Exact sum: 17.3 + 15 + 9.8 + 11.6 = 53.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 31Shree Vasu Logistics LtdSVLL | 51.9/100Thin evidence · provisional48% evidence | TURNING | 18.4/35 Revenue — · PAT — · OPM change 2.6 pp 19% evidence | 15.7/25 ROCE 12.9% · OPM 29% 95% evidence | 8.9/20 P/E 144× · PEG — 15% evidence | 8.9/20 RS sector -16.1% · RS bench 5.1% · 1Y -8.1%9 of 10 weeks ahead 70% evidence |
| Exact sum: 18.4 + 15.7 + 8.9 + 8.9 = 51.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 32Maagh Advertising & Marketing Services Ltd543624 | 49.6/100Thin evidence · provisional35% evidence | 18.3/35 Revenue — · PAT — · OPM change 275.6 pp 32% evidence | 9.0/25 ROCE -0.4% · OPM 55.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 12.3/20 RS sector — · RS bench 37% · 1Y —7 of 9 weeks ahead to 2025-03-19 25% evidence | |
| Exact sum: 18.3 + 9 + 10 + 12.3 = 49.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 33Indiqube Spaces Ltdthis pageINDIQUBE | 49.3/100Thin evidence · provisional46% evidence | ASLEEP | 20.9/35 Revenue 36.9% · PAT 23.6% · OPM change 5 pp 62% evidence | 9.6/25 ROCE 6.4% · OPM 62% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.8/20 RS sector — · RS bench -9.8% · 1Y -20.2%2 of 10 weeks ahead 25% evidence |
| Exact sum: 20.9 + 9.6 + 10 + 8.8 = 49.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 34Anzen India Energy Yield Plus TrustANZEN | 47.7/100Thin evidence · provisional46% evidence | ASLEEP | 17.4/35 Revenue 76.8% · PAT 100% · OPM change -9 pp 62% evidence | 8.9/25 ROCE 3.3% · OPM 75.5% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 11.4/20 RS sector — · RS bench 5.7% · 1Y 9.6%4 of 10 weeks ahead 25% evidence |
| Exact sum: 17.4 + 8.9 + 10 + 11.4 = 47.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 35Shree Rama Newsprint LtdRAMANEWS | 44.6/100Thin evidence · provisional46% evidence | 14.1/35 Revenue -20% · PAT 69.8% · OPM change -8 pp 40% evidence | 5.7/25 ROCE 1.9% · OPM 8% 71% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.8/20 RS sector 7.4% · RS bench 10.5% · 1Y 8.8%11 of 12 weeks ahead to 2026-04-19 70% evidence | |
| Exact sum: 14.1 + 5.7 + 10 + 14.8 = 44.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 36Tandhan Industries Ltd512062 | 42.6/100Thin evidence · provisional33% evidence | TURNING | 16.3/35 Revenue — · PAT -80% · OPM change — 50% evidence | 6.3/25 ROCE -0.3% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —4 of 4 weeks ahead 0% evidence |
| Exact sum: 16.3 + 6.3 + 10 + 10 = 42.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Indiqube Spaces Ltd's share price today?
Indiqube Spaces Ltd trades at ₹174, −20.2% over the past year. The company is valued at ₹3,684 Cr. The stock sits at 39% of its 52-week range of ₹134–₹238, −3.4% versus its 200-day average. On the tape, the price is in a downtrend, 34 weeks in. — as of 31 July 2026.
What were Indiqube Spaces Ltd's latest quarterly results?
Indiqube Spaces Ltd reported revenue of ₹401 Cr and a net loss of ₹23.0 Cr for the Mar 26 quarter. Earnings per share were ₹−1.07. The operating margin was 62.0%, 5.0 pp higher than a year earlier. — as of 31 July 2026.
What is Indiqube Spaces Ltd's revenue?
Indiqube Spaces Ltd reported revenue of ₹401 Cr in the Mar 26 quarter, +35.0% year on year. For the full FY26 fiscal year, revenue was ₹1,451 Cr (+37.0%). Over the last 6 years revenue compounded at 35.0% a year. — as of 31 July 2026.
What is Indiqube Spaces Ltd's profit?
Indiqube Spaces Ltd earned ₹−23.0 Cr of net profit in the Mar 26 quarter. Full-year FY26 profit was ₹−106 Cr. The operating margin ran 62.0% in the latest quarter. — as of 31 July 2026.
What is Indiqube Spaces Ltd's market cap?
Indiqube Spaces Ltd's market capitalisation is ₹3,684 Cr at a share price of ₹174. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
Does Indiqube Spaces Ltd pay a dividend?
No — Indiqube Spaces Ltd has recorded a dividend payout of 0% of profit in each of its last 7 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 31 July 2026.
How is Indiqube Spaces Ltd performing?
Indiqube Spaces Ltd is in a downtrend, 34 weeks in. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
Is Indiqube Spaces Ltd in an uptrend?
No — the price is in a downtrend (week 34 of stage 4), trading −3.4% versus its 200-day average and at 39% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Indiqube Spaces Ltd beating the market?
On recent form, yes — Indiqube Spaces Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 2 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.0 years the stock moved −20% against the NIFTY 500's +4% — behind the index over the full window. — as of 31 July 2026.
Will Indiqube Spaces Ltd's share price go up?
This page publishes no price forecast for Indiqube Spaces Ltd. What it measures instead: the share price is ₹174, the price is in a downtrend 34 weeks in. Direction is not something this site claims to know. — as of 31 July 2026.
Who owns Indiqube Spaces Ltd?
Promoters hold 60.1% of Indiqube Spaces Ltd, foreign institutions 2.2%, domestic institutions 14.3% and the public 23.4% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 31 July 2026.
Does Indiqube Spaces Ltd have too much debt?
It carries real leverage — Indiqube Spaces Ltd's debt-to-equity is 10.11, and operating profit covers the interest bill 2×. FY26 borrowings were ₹5,207 Cr against equity of ₹515 Cr. Read the returns on this page with that leverage in mind — as of 31 July 2026.
What is Indiqube Spaces Ltd's capex?
Indiqube Spaces Ltd spent ₹4,263 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹1,885 Cr, with ₹96.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Indiqube Spaces Ltd's cash flow?
Indiqube Spaces Ltd generated ₹920 Cr of operating cash flow in FY26 and ₹−965 Cr of free cash flow after ₹1,885 Cr of capital spending. Reported profit that year was ₹−106 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Where is Indiqube Spaces Ltd in its business cycle?
Indiqube Spaces Ltd's FY26 operating margin was 61.0%, against a 7-year band of 10.0%–61.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 62.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Indiqube Spaces Ltd story?
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Indiqube Spaces Ltd a stock worth studying right now?
This is not investment advice. The machine read: Indiqube Spaces Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.